Calcipotriene/betamethasone dipropionate: a new topical ointment for psoriasis

Reference

• Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin. Exp. Dermatol.26, 314–320 (2001).
   PubMed Web of Science ®Google Scholar
• Koo JY. Current consensus and update on psoriasis therapy: a perspective from the U.S. J. Dermatol.26, 723–733 (1999).
   PubMedGoogle Scholar
• Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom. A population-based study. Arch. Dermatol.141, 1537–1541 (2005).
   PubMed Web of Science ®Google Scholar
• Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol.137, 280–284 (2001).
   PubMed Web of Science ®Google Scholar
• Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J. Invest. Dermatol. Symp. Proc.9, 136–139 (2004).
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J. Clin. Pharm. Ther.25, 2–10 (2000).
   Web of Science ®Google Scholar
• Guenther L, Langley RG, Shear NH et al. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian psoriasis expert panel. J. Cut. Med. Surg.8(5), 321–337 (2004).
   PubMed Web of Science ®Google Scholar
• Guenther L. Tazarotene combination treatments in psoriasis. J. Am. Acad. Dermatol.43, S36–S42 (2002).
   Google Scholar
• Lamba S, Lebwohl M. Combination therapy with vitamin D analogs. Br. J. Dermatol.132, 675–682 (1995).
   PubMed Web of Science ®Google Scholar
• Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch. Dermatol.140, 408–414 (2004).
   PubMed Web of Science ®Google Scholar
• Richards HL, Fortune DG, Griffiths CEM. Adherence to treatment in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol.20, 370–379 (2006).
   PubMed Web of Science ®Google Scholar
• Fouéré S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J. Eur. Acad. Dermatol. Venereol.19(Suppl. 3), 2–6 (2005).
   PubMed Web of Science ®Google Scholar
• Bury Y, Ruf D, Hansen CM, Kissmeyer AM, Binderup L, Carlberg C. Molecular evaluation of vitamin D3 receptor agonists designed for topical treatment of skin diseases. J. Invest. Dermatol.116, 785–792 (2001).
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PCM. Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. Br. J. Dermatol.132, 675–682 (1995).
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PCM. In vivo effects of vitamin D3 analogues. J. Dermatol. Treat.9(Suppl. 3), S25–S29 (1998).
   Google Scholar
• Barna M, Bos JD, Kapsenberg ML, Snijdewint FG. Effect of calcitriol on the production of T-cell-derived cytokines in psoriasis. Br. J. Dermatol.136, 536–541 (1997).
   PubMed Web of Science ®Google Scholar
• Vissers WH, Berends M, Muys L, van Erp PE, de Jong EM, van de Kerkhof PC. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subset in chronic plaque psoriasis. Exp. Dermatol.13(2), 106–112 (2004).
   PubMed Web of Science ®Google Scholar
• Kragballe K, Fogh K, Sogaard H. Long-term efficacy and tolerability o topical calcipotriol in psoriasis. Acta Derma. Venereol. (Stockh.)71, 475–478 (1991).
   Google Scholar
• Ramsay CA, Berth-Jones J, Brundin G et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology189, 260–264 (1994).
   PubMed Web of Science ®Google Scholar
• Ellis JP, Griffiths WAD, Klaber MR. Long-term treatment of chronic plaque psoriasis with calcipotriol ointment in patients unresponsive to short-contact dithranol. Eur. J. Clin. Res.7, 247–257 (1995).
   Google Scholar
• Cullen SI. Long-term effectiveness and safety of topical calcipotriene for psoriasis. South Med. J.89, 1053–1056 (1996).
   PubMed Web of Science ®Google Scholar
• Berth-Jones J, Chu AC, Dodd WAH et al. A multi-centre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br. J. Dermatol.127, 266–271 (1992).
   PubMed Web of Science ®Google Scholar
• Tham SN, Lun KC, Cheong WK. A comparative study of calcipotriene ointment and tar in chronic plaque psoriasis. Br. J. Dermatol.131, 673–677 (1994).
   PubMed Web of Science ®Google Scholar
• Bruce S, Epinette WW, Funicella T et al. Comparative study of calcipotriol (MC 903) ointment and fluocinonide ointment in the tratment of psoriasis. J. Am. Acad. Dermatol.31, 755–759 (1994).
   PubMed Web of Science ®Google Scholar
• Cunliffe WJ, Berth-Jones J, Claudy A et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J. Am. Acad. Dermatol.26(5 Pt 1), 736–743 (1992).
   PubMed Web of Science ®Google Scholar
• Kragballe K, Gjertsen B, de Hoop D et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet337, 193–196 (1991).
   PubMed Web of Science ®Google Scholar
• Patel B, Siskin S, Krazmien R, Lebwohl M. Compatibility of calcipotriene with other topical medications. J. Am. Acad. Dermatol.38(6 Pt 1), 1010–1011 (1998).
   PubMed Web of Science ®Google Scholar
• van Rossum MM, van Erp PEJ, van de Kerkhof PCM. Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study. Dermatology203, 148–152 (2001).
   PubMed Web of Science ®Google Scholar
• Simonsen L, Hoy G, Didriksen E, Persson J, Melchior N, Hansen J. Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle. Drug Dev. Ind. Pharm.30(10), 1095–1102 (2004).
   PubMed Web of Science ®Google Scholar
• Kragballe K, Barnes L, Hamberg KJ et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br. J. Dermatol.139, 649–654 (1998).
   PubMed Web of Science ®Google Scholar
• Ortonne JP. Psoriasis: new therapeutic modality by calcipotriol and betamethasone dipropionate. Nouv. Dermatol.13, 746–751 (1994).
   Google Scholar
• Lebwohl M, Siskin SM, Epinette W, Breneman D, Funicella T, Kalb R, Moore J. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J. Am. Acad. Dermatol.35, 268–269 (1996).
   PubMed Web of Science ®Google Scholar
• Shupack JL, Jondreau L, Kenny C, Stiller MJ. Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis. Dermatology186, 129–132 (1993).
   PubMed Web of Science ®Google Scholar
• Beato M. Gene regulation by steroid hormones. Cell56, 335–344 (1989).
   PubMed Web of Science ®Google Scholar
• Meltzer EO. The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Allergy52, 33–40 (1997).
   PubMed Web of Science ®Google Scholar
• Gruyre PM, Girard MT, Morganelli PM, Manganiello PD. Glucocorticoid effects on the production and actions of immune cytokines. J. Steroid Biochem.30, 89–93 (1988).
   PubMedGoogle Scholar
• Guenther LC. Fixed-dose combination therapy for psoriasis. Am. J. Clin. Dermatol.5(2), 71–77 (2004).
   PubMed Web of Science ®Google Scholar
• Traulsen J. Bioavailability of betamethasone dipropionate when combined with calcipotriol Int. J. Dermatol.43(8), 611–617 (2004).
   PubMed Web of Science ®Google Scholar
• Traulsen J, Hughes-Formella BJ. The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate oinment compared with betamethasone dipropionate ointment. Dermatology207, 166–172 (2003).
   PubMed Web of Science ®Google Scholar
• Hansen J. Mixing the unmixable. Verbal communication at the Leo Satellite Symposium. Presented at 10th Congress of the European Academy of Dermatology and Venereology. Munich, Germany, 10–14 October 2001.
   Google Scholar
• Van Rossum MM, van Erp PEJ, van de Kerkhopf PCM. Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study. Dermatology.203, 148–152 (2001).
   PubMed Web of Science ®Google Scholar
• Kragballe K, van de Kerkhof PC. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J. Eur. Acad. Dermatol. Venereol.20(1), 39–44 (2006).
   PubMed Web of Science ®Google Scholar
• Murray S, Kragballe K, Douglas WS, van de Kerkhof PCV, Kidson P, Lowson D. Consistent responses from 4 week’s topical treatment of psoriasis with a two-compound product (calcipotriol/betamethasone dipropionate), regardless of baseline severity. J. Eur. Acad. Dermatol. Venereol.18(2), 352 (2004).
   Google Scholar
• Kaufmann R, Bibby AJ, Bissonnette R et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet®) is an effective once daily treatment for psoriasis vulgaris. Dermatology205, 389–393 (2002).
   PubMed Web of Science ®Google Scholar
• Kragballe K, Noerrelund KL, Lui H et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br. J. Dermatol.150, 1167–1173 (2004).
   PubMed Web of Science ®Google Scholar
• Anstey A, Kragballe K. A retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int. J. Dermatol.45(8), 970–975 (2006).
   PubMed Web of Science ®Google Scholar
• Parslew R, Traulsen J. Efficacy and local safety of a calcipotriol/betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris. Eur. J. Dermatol.15(1), 37–39 (2005).
   PubMed Web of Science ®Google Scholar
• Papp KA, Guenther L, Boyden B et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J. Am. Acad. Dermatol.48, 48–54 (2003).
   PubMed Web of Science ®Google Scholar
• Douglas WS, Poulin Y, Decroix J et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm. Venereol.82, 31–35 (2002).
   Web of Science ®Google Scholar
• Guenther L, Cambazard F, van de Kerkhof PCM et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br. J. Dermatol.147, 316–323 (2002).
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof P. A fixed combination of calcipotriol/betamethasone dipropionate improves quality of life in patients with psoriasis. Ann. Dermatol. Venereol.129(1 Pt 2), S769–S770 (2002).
   Google Scholar
• Guenther LC. Calcipotriol/betamethasone dipropionate: Daivobet®. Therapy2(3), 343–348 (2005).
   Google Scholar
• Ortonne JP, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomized, double-blind trial. Dermatology209(4), 308–313 (2004).
   PubMed Web of Science ®Google Scholar
• Peeters P, Ortonne JP, Sitbon R, Guignard E. Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris. Dermatology211(2), 139–145 (2005).
   PubMed Web of Science ®Google Scholar
• White S, Vender R, Thaci D et al. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. Am. J. Clin. Dermatol.7(3), 177–184 (2006).
   PubMed Web of Science ®Google Scholar
• Kragballe K, Austad J, Barnes L et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet®/Daivobet®/Taclonex®) in the treatment of psoriasis vulgaris. Br. J. Dermatol.154(6), 1155–1160 (2006).
   PubMed Web of Science ®Google Scholar
• Rogers C. Calcipotriol (Dovobet) ointment in combination with UVB therapy for psoriasis treatment. Dermatol. Nurs.18(3), 258–261 (2006).
   PubMedGoogle Scholar